SOLENO THERAPEUTICS INC Quarterly Nonoperating Income (Expense) in USD from Q3 2017 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Soleno Therapeutics Inc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2017 to Q2 2024.
  • Soleno Therapeutics Inc Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $3.01M, a 1936% increase year-over-year.
  • Soleno Therapeutics Inc Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $7.23M, a 1381% increase year-over-year.
  • Soleno Therapeutics Inc annual Nonoperating Income (Expense) for 2023 was $2.4M, a 626% increase from 2022.
  • Soleno Therapeutics Inc annual Nonoperating Income (Expense) for 2022 was $330K, a 46.6% decline from 2021.
  • Soleno Therapeutics Inc annual Nonoperating Income (Expense) for 2021 was $618K, a 94.7% decline from 2020.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $7.23M $3.01M +$2.87M +1936% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-07
Q1 2024 $4.36M $2.08M +$1.96M +1738% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $2.4M $2.61M +$2.49M +2008% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-07
Q3 2023 -$94K -$479K -$582K -565% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 $488K $148K +$94K +174% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-07
Q1 2023 $394K $113K +$64K +131% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q4 2022 $330K $124K -$49K -28.3% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-07
Q3 2022 $379K $103K -$43K -29.5% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 $422K $54K -$43K -44.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-08
Q1 2022 $465K $49K -$153K -75.7% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $618K $173K -$4.93M -96.6% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-22
Q3 2021 $5.55M $146K +$834K Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $4.72M $97K -$3.71M -97.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-10
Q1 2021 $8.43M $202K -$3.22M -94.1% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-10
Q4 2020 $11.7M $5.11M +$13M Oct 1, 2020 Dec 31, 2020 10-K 2022-03-31
Q3 2020 -$1.33M -$688K -$7.71M -110% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-10
Q2 2020 $6.38M $3.81M +$8.19M Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-28
Q1 2020 -$1.81M $3.42M +$5.48M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q4 2019 -$7.29M -$7.87M -$11.8M -300% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-03
Q3 2019 $4.51M $7.02M +$5.45M +348% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-10
Q2 2019 -$940K -$4.39M -$1.16M -36.1% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $223K -$2.05M -$2.24M -1209% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
Q4 2018 $2.46M $3.93M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-04
Q3 2018 $1.57M +$1.43M +1029% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-13
Q2 2018 -$3.22M Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $185K Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-13
Q3 2017 $139K Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.